Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M24,054Revenue (TTM) $M1,306Net Margin (%)-11.8Altman Z-Score22.9
Enterprise Value $M23,469EPS (TTM) $-0.8Operating Margin %-4.7Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-12.2Higher ROA y-yN
Price/Book22.910-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsY
Price/Sales17.35-y EBITDA Growth Rate %--Current Ratio2.9Lower Leverage y-yY
Price/Free Cash Flow494y-y EBITDA Growth Rate %-146.8ROA % (ttm)-9.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-25.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M211ROIC % (ttm)-15.4Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

INCY is held by these investors:

INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hoppenot HervePresident 2017-09-18Sell70,502$119.45-4.4view
Flannelly Barry PEVP & General Manager US 2017-09-14Sell714$124.25-8.1view
BAKER BROS. ADVISORS LPDirector, 10% Owner 2017-09-08Buy100,000$132-13.49view
Trower PaulPrincipal Accounting Officer 2017-09-05Sell3,000$138.41-17.5view
Siegel Eric H.EVP, General Counsel 2017-09-01Sell1,820$137.4-16.89view
SWAIN PAULA JEVP, Human Resources 2017-08-31Sell20,000$140-18.44view
Stein Steven HEVP & Chief Medical Officer 2017-08-29Sell2,111$125-8.65view
Trower PaulPrincipal Accounting Officer 2017-08-04Sell3,000$125.25-8.83view
Siegel Eric H.EVP, General Counsel 2017-08-01Sell1,820$132.92-14.09view
Stein Steven HEVP & Chief Medical Officer 2017-07-20Sell6,485$131.09-12.89view

Quarterly/Annual Reports about INCY:

News about INCY:

Articles On GuruFocus.com
Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell Sep 18 2017 
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Derma Sep 14 2017 
3 Stocks With Strong Movements Wednesday Morning Aug 30 2017 
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 Aug 30 2017 
2 Stocks Fall on Earnings Report Aug 29 2017 
Lilly and Incyte Provide Update on Baricitinib Jul 25 2017 
The Best- and Worst-Performing Stocks of Last Decade Jul 16 2017 
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results Jul 11 2017 
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to Jun 16 2017 
Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizuma Jun 13 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat